Immatics N.V., a clinical-stage biopharmaceutical company active in developing T cell-redirecting cancer immunotherapies, and Bristol Myers Squibb, have entered into a license, development and commercialization agreement for Immatics’ TCR Bispecific candidate, IMA401.   Immatics will receive an upfront payment of $150 million as well as up to $770 million in development, regulatory and commercial milestones, in addition to royalty payments on sales of IMA401. Immatics retains the options to co...